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The human tissue kallikrein family (KLK for protein; KLK for gene) includes 15 members. Twelve kallikreins, including KLK6, are
concurrently upregulated in ovarian cancer. However, the mechanism of this phenomenon remains unclear. In this study, we
measured KLK6 expression in a large series of ovarian tissue cytosols and examined possible mechanisms of KLK6 up-regulation in
ovarian cancer. Using a newly developed enzyme-linked immunosorbent assay (ELISA) with two monoclonal antibodies, we
quantified KLK6 expression in ovarian tissue cytosols, and confirmed the upregulation of KLK6 in ovarian cancer and its unfavourable
prognostic value. We then examined KLK6 mRNA expression using reverse transcription–polymerase chain reaction and established
its good concordance with KLK6 protein expression. This finding suggested that the KLK6 gene is under transcriptional regulation. We
then scrutinised a few mechanisms that could explain KLK6 upregulation. The relative abundance of two KLK6 mRNA transcripts was
studied; we found the same differential expression pattern in all samples, regardless of KLK6 levels. Genomic mutation screening of all
exons and the 50-flanking region of the KLK6 gene identified two linked single-nucleotide polymorphisms in the 50-untranslated region,
but neither correlated with KLK6 expression. Ovarian cell lines were separately treated with five steroid hormones. None of the
treatments produced significant effects on KLK6 expression. We conclude that KLK6 is transcriptionally upregulated in ovarian cancer,
but probably not through alternative mRNA transcript expression, genomic mutation, or steroid hormone induction.
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The human tissue kallikreins (KLKs) are a family of serine proteases
that are aberrantly expressed in several cancer types. Most strikingly,
12 kallikreins (KLK2, KLK3, KLK4, KLK5, KLK6, KLK7, KLK8,
KLK10, KLK11, KLK13, KLK14, and KLK15) are concurrently
upregulated in ovarian cancer (Borgono and Diamandis, 2004). Many
of these KLKs hold promise as prognostic and diagnostic biomarkers
(Yousef et al, 2001, 2003b; Diamandis et al, 2002, 2003; Borgono et al,
2003; Kishi et al, 2003; Luo et al, 2003; Scorilas et al, 2004). Several of
them have also been implicated in cancer progression and metastasis
(Bernett et al, 2002; Magklara et al, 2003; Becker et al, 2004).
Evidently, kallikrein upregulation in ovarian cancer has significant
relevance to cancer detection, management, and treatment. Under-
standing the mechanisms underlying their upregulation will allow for
a better definition of kallikreins’ role in ovarian cancer pathophysio-
logy and their clinical utility as prognostic and/or diagnostic
biomarkers or therapeutic targets.
The human tissue kallikrein genes (KLKs) are located in tandem
on chromosome 19q13.4, and show significant structural
homology (Yousef and Diamandis, 2001). Hence, the 12 kallikreins
concertedly overexpressed in ovarian cancer may share a common
regulation machinery. On this basis, we investigated the regulation
of one kallikrein, human tissue kallikrein 6, as a model system. The
findings may also prove applicable to other kallikreins. The KLK6
gene spans 10.5kb of genomic sequence on the kallikrein locus
(Figure 1A) (Yousef et al, 1999). The KLK6 protein is normally
expressed in adult brain, salivary gland, lung, colon, kidney,
breast, uterus, fallopian tube and placental tissues, and secreted
into numerous biological fluids (Diamandis et al, 2000; Petraki
et al, 2001). Ample evidence supports the overexpression/increase
of human KLK6 in both ovarian tumours and presurgical serum
of patients with ovarian cancer (Hoffman et al, 2002; Diamandis
et al, 2003; Yousef et al, 2003a). Nevertheless, few experiments
have been conducted to delineate the processes underlying this
upregulation.
In this study, we first quantified KLK6 expression, using a newly
developed immunoassay with two monoclonal antibodies, in a
relatively large series of ovarian cancer tissue specimens, and
confirmed the prognostic value of KLK6 for ovarian cancer. We
then assessed the correlation between KLK6 mRNA and KLK6
protein expression in order to determine whether KLK6 is under
transcriptional or translational upregulation. Lastly, we examined
the role of alternative transcripts, genetic aberrations, and steroid
hormones in the upregulation of KLK6 in ovarian cancer.
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tomic complexity. Through usage of alternative promoters and
other mechanisms, each KLK gene can generate numerous
alternative transcripts (Landry et al, 2003; Pampalakis et al,
2004). Some of these transcript variants have been shown to be
specifically overexpressed in ovarian cancer (Dong et al, 2001,
2003; Magklara et al, 2001). KLK6 has four alternative transcripts
encoding for the full-length KLK6 protein and four that may
encode for truncated proteins (Kurlender et al, 2005). The longest
KLK6 transcript (GenBank accession no. NM002774), also known
as the ‘classical transcript’, consists of 1512 nucleotides and seven
exons. KLK6 ‘alternative transcript 1’ has 1517 nucleotides
(GenBank accession no. AY318867); it lacks exon 1 but contains
a unique sequence at the 50-end of exon 2, denoted as exon 2A
(Figure 1B). Christophi et al (2004) found that these two mRNA
transcripts were expressed in a tissue-specific manner and were
differentially regulated in response to central nervous system
injury. Whether or not an analogous situation occurs in ovarian
cancer has not been investigated. To this end, we differentially
amplified these two transcripts and examined their expression
patterns in ovarian tumour tissues.
Another potential regulatory mechanism of the kallikreins is
genetic variation. Even though intragenic mutations have not
been identified for the kallikrein genes examined to date, KLK3
(Majumdar and Diamandis, 1999) and KLK10 (Liu et al, 1996), a
plethora of single-nucleotide polymorphisms (SNPs) exist within
KLK coding and promoter/enhancer regions and may have clinical
significance. For example, SNPs in the KLK3 promoter may
account for individual variation in serum prostate-specific antigen
levels and even cancer susceptibility (Tsuyuki et al, 1997; Xue et al,
2000; Cramer et al, 2003). Similarly, a nonsynonymous SNP in
exon 3 of KLK10 is associated with a higher prostate cancer risk
(Bharaj et al, 2002). The KLK6 locus in ovarian cancer patients has
not previously been scrutinised for genetic aberrations. Hence, we
sequenced all KLK6 exons and the 50-flanking region for ovarian
tumours with various KLK6 levels to determine if genetic
aberrations may account for the upregulation of KLK6 in ovarian
cancer.
Lastly, various in vitro and in vivo studies collectively
demonstrate that most, if not all, kallikreins are under steroid
hormone regulation in endocrine-related tissues and cell lines
(Borgono and Diamandis, 2004). Whereas some kallikreins, such
as KLK3 (Riegman et al, 1991) and KLK4 (Nelson et al, 1999), are
regulated by androgens, others, such as KLK5 (Yousef and
Diamandis, 1999), are more responsive to oestrogens. A role for
the steroid hormones in the regulation of KLK6 was first suggested
by the discovery of several hormone-related response elements,
including sterol regulatory element binding protein 1 and 2,
progesterone receptor binding site and cAMP response element-
binding protein in the 50-flanking region of the KLK6 gene
(Christophi et al, 2004). It was subsequently supported by the
findings that KLK6 was significantly up-regulated by norgestrel,
oestradiol and DHT in the breast cancer cell line BT474 (Yousef
et al, 1999). In this study, we examined whether or not steroid
hormones regulated KLK6 expression in ovarian cancer cell lines.
Our results confirmed the value of KLK6 as an unfavorable
prognostic biomarker for ovarian cancer. We also found KLK6 to
be under transcriptional regulation. Our data have further
suggested a minor role for alternative transcripts, genetic
mutations and steroid hormones in the regulation of human
kallikrein 6 in ovarian cancer.
MATERIALS AND METHODS
Tissue sample collection
We examined 259 patients with ovarian cancer, 49 with benign
ovarian conditions (including endometriosis, mucinous cystade-
nomas, serous cystadenomas, dermoid cysts, ovarian benign
teratomas and corpus luteum), 43 with nonovarian tumours that
metastasised to the ovary, and 34 apparently normal women.
Participants’ age ranged from 19 to 89 years, with a median of 58
years. All tissue samples were collected between April 1988 and
April 2003 at the Gynecologic Oncology and Breast Cancer Unit,
University of Turin, Italy. Identical specimen collection and
processing protocols were used for all participants. During
surgery, histologic examination was performed on the ovarian
tissues through intrasurgery frozen section analysis, which allowed
representative portions of each tumour containing more than 80%
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Figure 1 (A) Fifteen KLK genes are located in tandem on chromosome 19q13.4. (B) Genomic structures of the KLK6 ‘classical transcript’ (GenBank
accession no. NM002774) and the ‘alternative transcript 1’ (GenBank accession no. AY318867). Black regions denote coding exons, white regions denote
50- and 30-untranslated regions. Segment A arrows indicate primer locations for PCR amplification of all full-length KLK6 transcripts. Segments B and C
arrows indicate primer locations for differential PCR amplification of the KLK6 ‘classical transcript’ and the ‘alternative transcript 1’, respectively. Asterisks and
triangles indicate translation start sites and stop codons, respectively.
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stumour cells to be selected. All tumour samples collected were
snap-frozen in liquid nitrogen and stored at  801C until
extraction.
At the time of surgery, clinicopathologic information including
tumour stage, grade, histotype, residual tumour size, and
debulking success were documented. Tumours were staged
according to the Fe ´de ´ration Internationale des Gynaecologistes et
Obstetristes (FIGO) criteria (Pettersson, 1994) and graded accord-
ing to the Day et al, (1975) protocol. Tumour histotypes were
classified based on the World Health Organization (WHO) and
FIGO recommendations (Serov et al, 1973). Patients with ovarian
cancer at all stages (I–IV) and grades (1–3) were represented in
our study. Of the 259 ovarian tumours, the majority (110; 42%)
were of serous papillary histotype, followed by endometrioid (46;
18%), undifferentiated (33; 13%), mucinous (20; 8%), clear cell (18;
7%), or other nonepithelial types (24; 9%).
After surgery, we monitored the patients with ovarian cancer
for clinical response to chemotherapy and survival outcomes for
a median duration of 52 months. Follow-up information was
available for 232 patients, of whom 147 (63%) had relapsed and
117 (50%) had died.
All investigations were carried out according to the ethical
standards of the Helsiniki Declaration of 1975 (revised in 1983),
and were approved by the Institute of Obstetrics and Gynecology,
Turin, Italy, and the Institutional Review Board of Mount Sinai
Hospital, Toronto, Canada.
Preparation of cytosolic extracts
Snap-frozen tissues (20–100mg) were homogenised in liquid
nitrogen to a fine powder and added to 10 volumes of extraction
buffer (50mM Tris, pH 8.0, 150mM NaCl, 5mM EDTA, and 1% NP-
40 surfactant). The resulting mixtures were incubated on ice for
30min, with repeated vortexing every 10min, and then centrifuged
at 14000r.p.m at 41C for 30min. The supernatant (cytosolic
extract) was collected and stored at  801C until further experi-
ments. Total protein concentration of the extracts was determined
using the bicinchoninic acid method. Bovine serum albumin was
used as standard (Pierce Chemical Co., Rockford, IL, USA).
Measurement of KLK6 and CA125 protein expression in
ovarian cytosolic extracts
The concentration of KLK6 was quantified with a highly sensitive
and specific ‘sandwich-type’ immunoassay recently developed in
our laboratory. Two KLK6-specific monoclonal mouse antibodies
were used: the coating antibody (clone 27-4) and the detection
antibody (clone E24). The assay has a detection limit of 0.05mgl
 1,
a dynamic range up to 20mgl
 1, and does not cross-react with
any other members of the kallikrein family. White polystyrene
microtiter plates were first coated with 100ml of the coating
antibody solution (5mgl
 1 of the anti-KLK6 monoclonal antibody
clone 27-4 in 50mM Tris-HCl buffer, 0.05% sodium azide, pH 7.8).
The plates were incubated overnight at room temperature and then
washed three times with the washing buffer (5mM Tris-HCl buffer,
150mM NaCl, 0.05% Tween-20, pH 7.8). After washing, assay
standards (KLK6 recombinant protein produced in-house (Dia-
mandis et al, 2000)) or ovarian cytosolic extracts were added to the
wells in duplicates (100mlwell
 1) after being diluted two-fold in
assay buffer (50mM Tris-HCl buffer, 6% bovine serum albumin,
0.01% goat globulin, 0.005% mouse globulin, 0.1% bovine globulin,
0.5 M KCl, 0.05% sodium azide, pH 7.8). The plates were incubated
for 2h with shaking at room temperature and washed six times.
Subsequently, 100ml of the biotinylated detection antibody
solution (250mgl
 1 anti-KLK6 monoclonal antibody clone E24 in
assay buffer) was added to each well. The plates were incubated
for 1h at room temperature with shaking and washed six times.
Then, 100ml of alkaline phosphatase-conjugated (ALP) streptavidin
solution (Jackson ImmunoResearch) diluted 20000-fold in bovine
serum albumin buffer (6% bovine serum albumin, 50mM Tris-HCl
buffer, 0.05% sodium azide, pH 7.8) was added to each well. The
plates were incubated for 15min with shaking at room temperature
and washed six times. Lastly, 100ml of substrate buffer (0.1 M Tris-
HCl buffer, 0.1 M NaCl, 1mM MgCl2, pH 9.1), containing 1mM
diflunisal phosphate (DFP), was added to each well and incubated
for 10min with shaking at room temperature. Immediately after
incubation, 100ml of developing solution (1 M Tris-HCl buffer,
0.4 M NaOH, 2mM TbCl3,3 m M EDTA) was added to each well
and incubated for 1min with shaking at room temperature. The
fluorescence was measured with a time-resolved fluorometer, the
Cyberfluor 615 Immunoanalyzer (MDS Nordion), as described
elsewhere (Christopoulos and Diamandis, 1992). The KLK6
concentrations in ngml
 1 were converted to ng of KLK6mg
 1 of
total protein to adjust for the amount of tumour tissue extracted.
CA125 levels (KUmg
 1) of ovarian tissue samples were
measured with the Immulite 2000 assay (Diagnostic Products
Corporation, Los Angeles, CA, USA).
Statistical analysis
The distribution of KLK6 concentration in the ovarian tumour
cytosols was non-Gaussian. Therefore, we used the nonparametric
Mann–Whitney U-test to determine differences among the four
groups of samples. This test treated KLK6 concentration in
the tumour cytosols (ngmg
 1 of total protein) as a continuous
variable. We also assessed the association between KLK6 and
CA125 levels by determining the Spearman rank correlation
coefficient (r) and associated P-values. The ovarian cancer patients
were classified as KLK6-positive or KLK6-negative using the
median (2.83ngmg
 1) as the cutoff point. The relationship
between KLK6 expression and several clinicopathologic variables
was analysed with the w
2 test and the Fisher’s exact test, as
appropriate.
We then assessed the impact of KLK6 on patient survival by
calculating the hazard ratio (HR), which is the relative risk of
relapse or death in the KLK6-positive group, using the Cox
univariate and multivariate proportional hazard regression models
(Cox, 1972). Whereas progression-free survival (PFS) was defined
as the time interval between the first surgery and the identification
of recurrence or metastatic disease, overall survival (OS) was
defined as the time interval between the first surgery and death.
The multivariate models were adjusted for KLK6 expression in
tumours and other clinicopathologic variables that may affect
survival, including age, tumour grade, CA125 level, and histotype.
We only included patients for whom the status of all variables was
known in the multivariate models. Lastly, we constructed Kaplan
and Meier (1958) PFS and OS curves for the KLK6-positive and
KLK6-negative patients. The differences between the survival
curves were assessed for statistical significance using the log rank
test (Mantel, 1966). Patients were also classified as CA125-positive
and CA125-negative using the median 1330Umg
 1 as cutoff, and
we constructed Kaplan–Meier PFS and OS curves to evaluate the
prognostic significance of CA125.
RNA extraction and RT–PCR
We selected eight tumour tissues (H1–H8) that over-expressed
KLK6 (mean: 12.44ngmg
 1), eight samples (L1–L8) that ex-
pressed minimal KLK6 (mean: 0.06ngmg
 1), four benign ovarian
samples (B1–B4; mean KLK6 expression: 0.05ngmg
 1), and one
normal ovarian sample (N1; KLK6 expression: 0.02ngmg
 1). Total
RNA was isolated from these samples using the TRIzol
s method
(Life Technologies Inc., Gaithersburg, MD, USA) as directed by the
manufacturer. The yield and purity were determined spectro-
photometrically by measuring the absorbance of aliquots at 260
and 280nm. Two micrograms of total RNA were then reverse
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stranscribed using the SuperScript
t preamplification system (Life
Technologies Inc.) in a final volume of 20ml. As control for the
reverse transcription–polymerase chain reaction (RT–PCR), we
used commercially available human brain total RNA (Clonetech
Inc., Mountain View, CA, USA). To test the success of our reverse
transcription, 1ml of each cDNA product was PCR-amplified using
primers specific for the housekeeping gene, b-actin (for primer
sequences see Table 1), and visualised on 1.8% agarose gels stained
with ethidium bromide.
PCR amplifications
To amplify the mRNA transcript variants that encode the full-
length KLK6 protein (GenBank accession no. NM002774,
AY318867, AY318869, and BC015525), we designed primers (for
sequences see Table 1; Figure 1B) that anneal to a common region
for all four variants (nucleotides 257–709; numbers refer to
GenBank accession no. AY318867).
One microliter of first-strand cDNA template was amplified in a
25ml reaction mixture containing 10  PCR buffer (Qiagen Inc.,
Mississauga, ON, USA), 100mM dNTPs (deoxynucleoside triphos-
phates), 2.5U of HotStar Taq DNA polymerase (Qiagen Inc.) and
100ng of the appropriate primers in an Eppendorf thermocycler.
Cycling conditions were as follows: enzyme activation at 951C for
15min; 32 cycles of denaturation at 951C for 30s, annealing at 651C
for 30s, and extension at 721C for 30s; followed by a final
extension at 721C for 10min. The KLK6 PCR product was
visualised on 1.8% agarose gels stained with ethidium bromide.
Gels were photographed under UV light with the Speedlight Gel
Documentation System (Lightools Research, Encinitas, CA, USA).
Two independent observers examined the images to determine the
presence or absence of KLK6 PCR-generated bands. Each
amplification experiment was performed twice to ensure reprodu-
cibility of data.
To differentially amplify the ‘classical transcript’ and ‘alternative
transcript 1’ (GenBank accession no. NM002774 and AY318867,
respectively), which differ only in their 50-untranslated regions
(UTRs), we used two unique forward primers and the same reverse
primer (for sequences, see Table 1; Figure 1B). The PCR reactions
amplified nucleotides 1–285 for the ‘classical transcript’ (numbers
refer to the sequence NM002774), and nucleotides 1–290 for
‘alternative transcript 1’ (numbers refer to the sequence
AY318867). We ensured that the two primer sets had comparable
annealing efficiency by conducting parallel PCR reactions with
each primer set and equal amounts of plasmid DNA. These
reactions generated PCR bands of similar intensity (Figure 5B).
Cycling conditions for both amplifications were the same as
described above, except for the annealing temperature, which was
611C for both reactions. Only tumour samples H1–H8, which
expressed high kallikrein 6 protein and mRNA, were used in this
experiment. Normal human brain and ovarian cDNA templates
were used as controls.
Genomic DNA extraction and mutation screening
An even representation of ovarian tumour tissues expressing high
KLK6 (n¼9; mean¼11.72ngmg
 1) and low KLK6 (n¼9; mean-
0.09ngmg
 1), benign ovarian tissues (n¼8; mean: 0.09ngmg
 1),
non-ovarian tumours that metastasised to the ovary (n¼6; mean:
0.04ngmg
 1), and normal ovarian tissues (n¼13; mean:
0.06ngmg
 1) were selected for genomic DNA extraction and
sequencing. DNA was extracted using the QIAamp DNA mini Kit
(Qiagen Inc.) according to the manufacturer’s protocols, and its
yield and purity were determined spectrophotometrically by
measuring the absorbance of aliquots at 260 and 280nm.
To design primers for mutation screening, we used KLK6
‘alternative transcript 1’ as template, as it was found to be the
dominant transcript in the ovaries. We designed seven sets of
primers amplifying all exons and their flanking intronic sequences,
as well as the 50-flanking region (601bp upstream of the putative
transcription start site, numbers refer to the KLK6 genomic
sequence, GenBank accession no. AF149289). Sequences of all
primers are shown in Table 1. Polymerase chain reaction was
carried out with 2mg of genomic DNA in a 25ml reaction mixture
containing 10  reaction buffer, 100mM of dNTP, 1U of Pfu Turbo
Polymerase (Stratagene, La Jolla, CA, USA), and 100ng of the
appropriate primers. Pfu Turbo DNA polymerase was employed
because of its high fidelity. The PCR cycling conditions were as
follows: 3min of enzyme activation at 951C, 35 cycles of 1min
denaturation at 951C, 45s of annealing at a primer-dependent
temperature (Table 1), and 1min of extension at 721C, followed by
10min of final extension at 721C. The extension time for each cycle
was prolonged to 1min and 30s when amplifying the 50-flanking
region and exon 7, to compensate for the length of these PCR
products. The success of the PCR reactions were evaluated by
running 5ml of each PCR product on 1.8% agarose gels stained
with ethidium bromide. The remaining of the PCR products was
purified by treatment with exonuclease I (0.25U) and shrimp
alkaline phosphatase (0.25U) (USB, Cleveland, OH, USA).
Mixtures were incubated at 371C for 15min, and then at 851C
for 15min. After purification, PCR products were directly
sequenced using an automated DNA sequencer. The PCR product
was sequenced again in the opposite direction if sequencing results
showed a departure from the published sequence in GenBank
(accession no. AF149289).
Cell lines and hormonal stimulation experiments
BG-1, CaOV3, and OVCAR-3 are ovarian cancer cell lines,
purchased from the American Type Culture Collection (ATCC,
Rockville, MD, USA) and grown in RPMI media (Invitrogen,
Table 1 Primer sequences used for PCR amplification and DNA
sequencing
Amplicon Sequence (50-30)
PCR product
length (bp)
Annealing
temp (
oC)
F: ATCTGGCACCACACCTTCTA
b-Actin R: CGTCATACTCCTGCTTGCTG 835 62
Four KLK6 F: GAAGCTGATGGTGGTGCTGAGTCTG
Transcripts R: AGACAGCAGATGGTGATTTCCCTGAC 454 65
Classical F: AGGCGGACAAAACCCGATTGTTC
Transcript R: CTGCAGCAATCAGACTCAGCACCAC 285 61
Alternative F: AGAAGCATCTGGGGACAGAACCAG
Transcript 1 R: CTGCAGCAATCAGACTCAGCACCAC 290 61
KLK6 F: GTGCTGGGGGTGCAGGGAGG
50-Flanking R: CCCCCACGCTCTGCTCTTGG 503 67
F: CTCCCTTCCCTGGAGGCCTG
Exon 2A+2 R: GGGAGTTTTCCTCGGAGCCTG 476 66
F: GGAGAGGATGCAGAGGGAGCAGACA
Exon 3 R: TCCCCAATACCAGCCTCTTCTCC 210 65
F: ACTGGAGTTCATGTTGAGGGGGATG
Exon 4 R: CCTATGTCACCTCCTGCCTGACATC 614 66
F: CCCAGCTGGGGAAGACTGTGGG
Exon 5 R: TGGCCCCTCACCAATTTTCCC 457 67
F: GAGGGGTGCCAATAGAAAAGAGG
Exon 6 R: GTGACTTCGTCCTGTCCCTGGCTG 314 66
F: ATCTGACTTTCTCCCTCTTTCCTGC
Exon 7 R: GTGCCTTCCTGGAGGGGAGG 816 65
F¼forward, R¼reverse. Thirty-five cycles per PCR except for the ‘Four KLK6
Transcripts’ (32 cycles). (PCR¼polymerase chain reaction).
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sCarlsbad, CA, USA) containing 10% fetal bovine serum (FBS)
(HyClone Laboratories, Inc., Logan, UT, USA). The human ovarian
surface epithelium (hOSE) cell line was obtained from Dr Nelly
Auersperg at the University of British Columbia. It was originally
established by scraping human ovarian surface epithelial cells
(n¼3) from the ovarian surface of overtly normal ovaries during
laparoscopies for nonmalignant disorders (Kruk and Auersperg,
1992). The hOSE cells were cultured in medium 199:MCDB105
(1:1) (Life Technologies Inc.) with 10% FBS (HyClone).
All cell lines were cultured in plastic flasks to near confluency,
aliquoted into six-well tissue culture plates, and then cultured to
75% confluency. Twenty-four hours before the hormonal stimula-
tion treatments, the culture medium was changed into each cell
line’s respective medium containing 10% charcoal-stripped fetal
bovine serum. Cells were grown in the new media for 24h.
The steroid hormones used were estroadiol, aldosterone,
dihydrotestosterone (DHT), dexamethasone, and norgestrel. Each
steroid hormone was dissolved in 100% ethanol, and added to the
culture media in each well at a final concentration of 10
 8 M and
less than 1% ethanol. Controls were the cells stimulated with an
equal amount of ethanol only. All cells were grown for 7 days after
stimulation and the cell culture supernatant was collected for
KLK6 measurement using the aforementioned immunoassay.
These experiments were repeated three times to ensure reprodu-
cibility of results.
Table 2 Tissue KLK6 concentrations in four groups of patients
KLK6 (ngmg
 1) Mean7s.e.
a Median Range P-value
b
Normal (N¼34) 0.3170.13 0.05 0.01–4.11 0.1
c
Benign (N¼49) 0.8270.36 0.09 0.01–16.0 o0.001
d
Ovarian cancer (N¼259) 5.8970.55 2.83 0.01–64.96 o0.001
e
Nonovarian cancer metastatic
to ovary (N¼43)
0.8370.28 0.09 0.01–8.56 o0.001
f
as.e.: Standard error.
bCalculated by Mann—Whitney test.
cBetween normal and
benign groups.
dBetween normal and ovarian cancer groups.
eBetween benign and
ovarian cancer groups.
fBetween ovarian cancer and nonovarian cancer metastatic to
ovary.
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Figure 2 Distribution of KLK6 concentration in ovarian tissue cytosols. (A) Distribution of KLK6 concentration in apparently healthy women (normal);
women with benign ovarian conditions (benign); women with ovarian cancer; and women with nonovarian cancers that metastasised to the ovaries
(nonovarian metastases). (B) Distribution of KLK6 concentration in women with different stages of ovarian cancer. (C) Distribution of KLK6 concentration in
various histotypes of ovarian cancer. Horizontal lines represent medians. n, number of samples.
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Distribution of KLK6 concentration in ovarian tissues
The KLK6 protein concentration in normal ovarian tissues ranged
from 0.01 to 4.11ngmg
 1 of total protein, with a median of
0.05. Both benign ovarian tissues (median: 0.09; range: 0.01–
16ngmg
 1) and nonovarian tumours that metastasised to the
ovary (median: 0.09; range: 0.01–8.56ngmg
 1) also had relatively
low KLK6 expression. Conversely, the protein concentration of
KLK6 in the 259 ovarian tumour cytosols ranged from 0.01 to
65ngmg
 1 of total protein, with a median of 2.83 (Table 2;
Figure 2A). We performed the nonparametric Mann-Whitney U-
test to analyse the differences in KLK6 expression among the four
groups of ovarian tissue samples. KLK6 expression in ovarian
tumour cytosols was found to be 57-fold higher than normal and
31-fold higher than benign and nonovarian metastatic tumours
(Po0.0001). We used the median as the cutoff value to categorise
the ovarian tumours as KLK6-positive or KLK6-negative.
Relationships between KLK6 status and other
clinicopathologic variables
We categorised KLK6-positive and KLK6-negative patients accord-
ing to clinicopathologic variables including tumour stage, grade,
histotype, debulking success and response to chemotherapy
(Table 3). The strength of the relationships between KLK6 and
these variables was evaluated with either the w
2 test or the Fisher’s
exact test, as appropriate. We found that patients with KLK6-
positive tumours more frequently had late stage (stage III/IV)
disease (Po0.001) (Figure 2B), higher tumour grades (P¼0.04),
suboptimal debulking (P¼0.002), and serous and undifferentiated
histotypes (Po0.001) (Figure 2C); but KLK6 expression had no
relationship with response to chemotherapy. A weak positive
correlation between tissue CA125 and KLK6 expression in ovarian
cancer (Spearman correlation rs¼0.566; Po0.001) was also
observed (Figure 3).
Univariate and multivariate survival analysis
The association between KLK6 protein expression and patient
survival is summarised in Table 4. Univariate Cox regression
analysis showed that KLK6-positive patients were at an increased
risk of relapse (HR¼1.56; P¼0.008) and death (HR¼1.46;
P¼0.045) in comparison with KLK6-negative patients. When
KLK6 expression was treated as a continuous variable (after
logarithmic transformation of data), its correlation with patient
survival remained significant (HR¼1.45 for PFS, Po0.001; and
1.37 for OS, P¼0.004). Other variables such as histological type
and grade, but not age, had even higher HRs for both PFS and OS.
In multivariate Cox regression analysis, the relationship between
KLK6 status and survival outcome was no longer significant.
The same was true for patient age. Tumour grade remained a
significant predictor of both PFS and OS, though histological type
was no longer associated with OS. Kaplan–Meier survival curves
showed significant association between KLK6 status and both PFS
and OS (Figure 4A and B). On the contrary, Kaplan–Meier survival
curves showed that CA125 did not bear prognostic significance
(Figure 4C and D).
Expression of KLK6 mRNA transcripts in ovarian tumours
The collective expression of all KLK6 mRNA transcripts encoding
the full-length protein was assessed in 16 ovarian tumour samples,
eight with KLK6 overexpression (H1–H8) and eight with minimal
KLK6 expression (L1–L8). Whereas KLK6 mRNA expression was
significant in H1–H8, it was undetectable in L1–L8 (Figure 5A).
For some of the high-KLK6 expressing samples, we observed an
Table 3 Relationship between tissue KLK6 status and other variables in
ovarian cancer patients
No. of patients (%)
Variable Patients KLK6 negative
a KLK6 positive P-value
Stage
I 65 47 (72.3) 18 (27.7) o0.001
b
II 20 9 (45.0) 11 (55.0)
III 143 62 (43.4) 81 (56.6)
IV 18 4 (22.2) 14 (77.8)
x
c 13
Grade
G1 58 33 (56.9) 25 (43.1) 0.04
b
G2 46 28 (60.9) 18 (39.1)
G3 139 59 (42.4) 80 (57.6)
x
c 16
Histotype
Serous 110 39 (35.5) 71 (64.5) o0.001
b
Endometrioid 46 30 (65.2) 16 (34.8)
Mucinous 20 14 (70.0) 6 (30.0)
Clear cell 18 12 (66.7) 6 (33.3)
Undifferentiated 33 10 (30.3) 23 (69.7)
Other nonepithelial 24 20 (83.3) 4 (16.7)
x
c 8
Debulking success
d
SD 102 38 (37.3) 64 (62.7) 0.002
e
OD 140 80 (57.1) 60 (42.9)
x
c 17
Response to CTX
f
NC/PD 18 8 (44.4) 10 (55.6) 0.81
b
PR 41 19 (46.3) 22 (53.7)
CR 180 91 (50.6) 89 (49.4)
NE 20
aCutoff¼2.83mgmg
 1 (50th percentile).
bw
2 test.
cStatus unknown.
dOD: optimal
debulking (0–1cm), SD: suboptimal debulking (41cm).
eFisher’s exact test.
fCTX¼chemotherapy; NC¼no change; PD¼progressive disease; CR¼complete
response; PR¼partial response; NE¼not evaluated.
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Figure 3 Correlation between tissue CA125 and KLK6 levels. rs,
Spearman’s correlation coefficient.
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sadditional, shorter, and much weaker band generated by PCR
amplification. After sequencing, we confirmed this band to
represent a previously identified splice variant (GenBank accession
no. AY279383), which lacks exon 4 (Kurlender et al, 2005). Four
benign and one normal ovarian tissue samples expressing low
KLK6 were used as controls. All had undetectable KLK6 mRNA
expression (Figure 5A).
We also examined the relative expression of two most abundant
KLK6 mRNA transcripts. For each of tumour samples H1–H8, we
assessed the differential expression of the ‘classical transcript’ and
‘alternative transcript 1’. Normal brain and ovarian cDNA
templates were used as controls. For all samples studied, excluding
normal ovarian tissues which showed no expression for either
transcript, ‘alternative transcript 1’ was by far the dominant
transcript (GenBank accession no. AY317768) (Figure 5B).
SNPs in the 50-UTR of KLK6 ‘alternative transcript 1’
As ‘alternative transcript 1’ was found to be the more abundant
transcript (Figure 5B), we used it as the template for our mutation
screening experiments. We amplified and sequenced all KLK6
exons and the 50-flanking region. No mutations were found in any
of the coding exons of KLK6. However, we identified two
previously unpublished single nucleotide polymorphisms (SNPs)
located in a (GT)4 microsatellite in the 50-untranslated region
(exon 2A). The SNPs are located at 55 and 60bp downstream of the
putative transcription start site (Pampalakis et al, 2004), and 195
and 190bp upstream of the start codon, respectively. G was the
more frequent allele for both SNPs. The two SNPs were in linkage
disequilibrium (the dependence of an allele at one locus on alleles
at another locus), as the T allele was found at the second SNP only
if the T allele was also present at the first SNP. We observed six
different haplotypes across all samples studied. None of the
haplotypes significantly correlated with KLK6 expression or
sample type.
According to the published GenBank sequence AY318876, the
microsatellite in this region consists of four GT repeats (GT)4.
However, according to our findings, the most prevalent haplotype
(51%) has a (GT)3 microsatellite owing to a single nucleotide
change from T to G at basepair 55. As all tumour samples were
collected from Italian subjects, we examined if the difference in the
microsatellite length was due to race. We sequenced three normal
ovarian tissues obtained from Mount Sinai Hospital, Ontario,
Canada, and found them to also have Haplotype B.
Hormonal regulation of KLK6 in ovarian cancer
We examined the effects of steroid hormones on KLK6 expression
in BG-1, CaOV3 and OVCAR-3 epithelial ovarian cancer cell lines,
as well as the hOSE cell line. As illustrated in Figure 6, none of the
steroid hormones produced any significant changes in KLK6
expression for the ovarian cancer cell lines. The hOSE cell line did
not produce detectable KLK6 under any treatment conditions
(data not shown).
DISCUSSION
Ovarian cancer is the most lethal gynaecologic malignancy in
developed countries (Mor et al, 2005). The high morality rate of
this disease could be attributed to difficulties underlying its early
detection, the disease’s intrinsic aggressiveness, and our meagre
understanding of its aetiology. The development of novel
diagnostic and prognostic biomarkers will facilitate early detection
and more individualised and efficient treatment plans for ovarian
cancer patients. Of the plethora of novel potential biomarkers
identified in recent years, those that also have clinical relevance to
cancer initiation and progression are the most valuable, as they
may serve the dual role as biomarkers as well as therapeutic
targets.
Table 4 Univariate and multivariate analysis of tissue KLK6 with regard to PFS and OS in ovarian cancer
Progression-free survival Overall survival
Variable HR
a 95% CI
b P-value HR
a 95% CI
b P-value
Univariate analysis
KLK6
Negative 1.00 1.00
Positive 1.56 1.12–2.17 0.008 1.46 1.01–2.11 0.045
Continuous logarithmic variable 1.45 1.19–1.75 o0.001 1.37 1.11–1.71 0.004
CA125
Negative 1.00 1.00
Positive 1.13 0.82–1.57 0.45 1.08 0.75–1.55 0.68
Continuous logarithmic variable 1.15 0.96–1.38 0.11 1.05 0.85–1.27 0.66
Histological type
c 1.95 1.40–2.72 o0.001 1.61 1.12–2.31 0.01
Stage (ordinal) 2.62 2.08–3.31 o0.001 2.52 1.92–3.29 o0.001
Grading (ordinal) 1.90 1.50–2.41 o0.001 1.58 1.09–2.28 0.014
Age (ordinal) 1.013 1.00–1.026 0.046 1.02 1.01–1.03 0.006
Multivariate analysis
KLK6
Negative 1.00 1.00
Positive 1.04 0.73–1.49 0.83 1.04 0.69–1.56 0.84
Continuous logarithmic variable 1.15 0.88–1.51 0.28 1.24 0.92–1.68 0.16
CA125
Negative 1.00 1.00
Positive 0.94 0.66–1.34 0.74 0.92 0.62–1.37 0.68
Continuous logarithmic variable 0.87 0.66–1.15 0.34 0.75 0.54–1.03 0.08
Stage (ordinal) 2.29 1.75–2.99 o0.001 2.28 1.63–3.05 o0.001
Histological type
c 1.15 0.81–1.65 0.43 0.99 0.66–1.47 0.96
Grading (ordinal) 1.27 0.97–1.68 0.078 1.31 0.94–1.80 0.11
Age (ordinal) 0.99 0.98–1.01 0.86 1.01 0.99–1.027 0.26
aHazard ratio (HR) estimated from Cox proportional hazard regression model.
bConfidence interval of the estimated HR.
cSerous vs others.
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associated biomarkers (Duffy, 1996). Accumulating evidence
suggests that the human tissue kallikreins, a family of secreted
serine proteases ubiquitously expressed in human tissues and
biological fluids, have prognostic and diagnostic value in various
cancer types (Borgono and Diamandis, 2004). Some KLKs have
also been shown to play a role in extracellular matrix degradation,
which in turn facilitates tumour invasion and metastasis (Borgono
et al, 2004). Human kallikrein 6, in particular, is elevated in
presurgical serum of ovarian cancer patients (Diamandis et al,
2003), as well as overexpressed in ovarian tumour tissues
(Hoffman et al, 2002), and bears prognostic and diagnostic
significance. KLK6 is a trypsin-like enzyme that can degade in
vitro laminin and fibronectin (Bernett et al, 2002), as well as other
basic constituents of the extracellular matrix (ECM) and the
basement membrane (Magklara et al, 2003), and could be linked to
tumour cell growth and malignant transformation. Hence, KLK6
may also serve as a therapeutic target for ovarian cancer. To
further clarify KLK6’s clinical utility and its role in ovarian cancer
pathophysiology, we aimed to delineate the molecular processes
underlying KLK6 overexpression in ovarian cancer.
We first conducted a validation study to confirm the prognostic
significance of KLK6 in a large group of ovarian tumour tissues
using a new immunoassay of higher sensitivity and specificity than
previously reported (Diamandis et al, 2000). KLK6 protein was
expressed at low levels in normal and benign ovarian tissues.
Conversely, the KLK6 expression in ovarian tumour cytosols was
significantly upregulated. This increase correlated with cancer
stage (Figure 2B). Metastatic tumours to the ovary from primary
gastrointestinal, endometrial, uterine, or breast cancers expressed
low levels of KLK6 that were comparable with benign ovarian
tissues. Hence, the up-regulation of KLK6 seems to be specific to
ovarian cancer. Figure 2C indicates that most tumours with KLK6
up-regulation were of epithelial origin, and especially of serous
and undifferentiated histotypes.
Univariate Cox regression analyses confirmed that KLK6 was
significantly correlated with survival (Table 4). Kaplan–Meier
survival curves confirmed that KLK6 was a significant and much
stronger prognostic biomarker than CA125 for both PFS and OS
(Figure 4). In multivariate Cox regression models adjusted for
tumour grade, histotype, CA125 and patient age, the relationship
between KLK6 expression and patient survival was no longer
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Figure 4 Kaplan–Meier survival curves for progression-free survival (A) and overall survival (B) in patients with KLK6-positive and KLK6-negative ovarian
tumours. n, number of samples. Kaplan–Meier survival curves for progression-free survival (C) and overall survival (D) in patients with CA125-positive and
CA125-negative ovarian tumours. n, number of samples.
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prognostic indicator for ovarian cancer, it appears to be a
surrogate marker for other clinicopathological variables such as
tumour stage, grade, histotype and debulking success. Recent
evidence indicates that multiparametric strategies that merge
diagnostic and prognostic information provided by several
individual biomarkers yield more informative and accurate
medical predictions (Woolas et al, 1993, 1995; Zhang et al, 1999;
Mor et al, 2005). Therefore, KLK6 could be used in conjunction
with other kallikreins, as well as non-kallikrein biomarkers in
future multiparametric prognostic tests for ovarian cancer.
To delineate the processes underlying the overexpression of
KLK6 in ovarian cancer, we first determined whether KLK6 was
under transcriptional or translational upregulation. We assessed
KLK6 mRNA expression in tumours with high or low KLK6
protein concentration and correlated these two parameters.
Excellent concordance between KLK6 protein and mRNA expres-
sion was observed (Figure 5), rendering evidence for transcrip-
tional regulation.
We evaluated the differential expression of the two most
abundant transcripts of KLK6. Previous studies showed that
‘alternative transcript 1’ was expressed in both peripheral tissues
(though the ovary was not examined) and the central nervous
system, whereas the ‘classical transcript’ was only expressed in the
central nervous system (Christophi et al, 2004; Pampalakis et al,
2004). We confirmed that the ‘classical transcript’ was highly
expressed only in the brain, and weakly expressed or absent in all
ovarian tissues. KLK6 ‘alternative transcript 1’ was the dominant
transcript in all samples examined (Figure 5). Therefore,
differential expression of alternative transcripts cannot account
for KLK6 upregulation in ovarian cancer.
Our genomic mutation screening experiments found no
mutations except two novel exonic SNPs within a (GT)4
microsatellite in the 50-UTR of ‘alternative transcript 1’ (þ55 G/T,
þ60 G/T). The SNPs were not located in any putative promoter
region or known steroid hormone response elements regulatory
regions (Christophi et al, 2004). No consensual changes were
observed within any sample types. Previous experiments have
indicated a tendency for SNPs in the KLK locus to exhibit strong
linkage disequilibrium (Cramer et al, 2003; Borgono and
Diamandis, 2004). Indeed, these two SNPs were linked to each
other.
Lastly, we evaluated the role of steroid hormones in the
regulation of KLK6 in ovarian cancer. Sex steroid hormones have
previously been implicated in the pathogenesis and growth
regulation of ovarian cancers (Hoover et al, 1977; Langdon et al,
1990; Godwin et al, 1993; Chien et al, 1994). Hormonal regulation
of KLKs in ovarian cancer has only been demonstrated in the
ovarian cancer cell line, BG-1, where KLK9 was under the
regulation of oestrogen and progesterone (Yousef et al, 2001). In
this study, we found that steroid hormones play a minor role in the
regulation of KLK6 in ovarian cancer. It remains to be elucidated
why steroid hormones regulate KLK6 in breast cancer cell lines
such as BT474 (Yousef et al, 1999), but not in receptor-positive
ovarian cancer cell lines.
In conclusion, we confirmed that KLK6 is significantly
upregulated in ovarian cancer and serves as an unfavourable
prognostic biomarker. We also found that KLK6 is under
transcriptional regulation. Nevertheless, the overexpression of
KLK6 in ovarian cancer is probably not due to differential
expression of alternative transcripts, mutations in the exons and
proximal 50-flanking region, or steroid hormone regulation.
Various other transcriptional regulation mechanisms remain to
be tested for their roles in the upregulation of the KLKs in ovarian
cancer. As subgroups of kallikreins are frequently coexpressed in
tissues, transcription of KLK genes may be regulated by cis-acting
locus control regions (Li et al, 1999). In fact, such a mechanism has
been implicated in controlling the salivary gland-specific expres-
sion of the rat kallikrein gene family (Smith et al, 1992). Future
studies should investigate whether a similar mechanism is at work
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sin human ovaries. Furthermore, the promoter region of ‘alternative
transcript 1’ has not been fully elucidated, and the actual
transcription start site is not ascertained. Characterisation of the
KLK6 promoter would facilitate future efforts to study the
regulation of KLK6, including studying the roles of transcription
factors. Lastly, chromosome 19q13 is reportedly rearranged in
numerous types of solid tumours (Whang-Peng et al, 1984; Tanaka
et al, 1989; Bello and Rey, 1990; Pejovic et al, 1991, 1992; Jenkins
et al, 1993). Potential gene amplification of KLK6 in ovarian cancer
has also been suggested (Ni et al, 2004). Therefore, the role of
chromosomal rearrangements of the KLK locus in cancer should
be examined in future investigations.
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Figure 6 Ovarian cancer cell lines BG-1, CaOV3, OvCAR3 were
stimulated with 10
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norgestrel, or alcohol (control). KLK6 protein concentration in supernatants
was quantified by immunoassay. No major changes were seen with any
steroid hormone stimulation. Error bars represent standard errors of the
mean.
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